메뉴 건너뛰기




Volumn 103, Issue 2, 2012, Pages 342-349

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers

Author keywords

[No Author keywords available]

Indexed keywords

CH 5164840; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; PROTEIN KINASE B; UNCLASSIFIED DRUG;

EID: 84856471585     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02144.x     Document Type: Article
Times cited : (23)

References (32)
  • 1
    • 25844519550 scopus 로고    scopus 로고
    • HSP90 and the chaperoning of cancer
    • Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
    • (2005) Nat Rev Cancer , vol.5 , pp. 761-772
    • Whitesell, L.1    Lindquist, S.L.2
  • 2
    • 28244444919 scopus 로고    scopus 로고
    • Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
    • da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65: 10686-91.
    • (2005) Cancer Res , vol.65 , pp. 10686-10691
    • da Rocha Dias, S.1    Friedlos, F.2    Light, Y.3    Springer, C.4    Workman, P.5    Marais, R.6
  • 3
    • 30444441778 scopus 로고    scopus 로고
    • V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
    • Grbovic OM, Basso AD, Sawai A et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103: 57-62.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 57-62
    • Grbovic, O.M.1    Basso, A.D.2    Sawai, A.3
  • 4
    • 22244485706 scopus 로고    scopus 로고
    • Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
    • Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005; 65: 6401-8.
    • (2005) Cancer Res , vol.65 , pp. 6401-6408
    • Shimamura, T.1    Lowell, A.M.2    Engelman, J.A.3    Shapiro, G.I.4
  • 5
    • 0036494113 scopus 로고    scopus 로고
    • Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin
    • Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res 2002; 62: 1559-66.
    • (2002) Cancer Res , vol.62 , pp. 1559-1566
    • Bonvini, P.1    Gastaldi, T.2    Falini, B.3    Rosolen, A.4
  • 6
    • 0033863883 scopus 로고    scopus 로고
    • The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome
    • An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000; 11: 355-60.
    • (2000) Cell Growth Differ , vol.11 , pp. 355-360
    • An, W.G.1    Schulte, T.W.2    Neckers, L.M.3
  • 7
    • 0141484615 scopus 로고    scopus 로고
    • A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    • Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-10.
    • (2003) Nature , vol.425 , pp. 407-410
    • Kamal, A.1    Thao, L.2    Sensintaffar, J.3
  • 8
    • 34248195608 scopus 로고    scopus 로고
    • High HSP90 expression is associated with decreased survival in breast cancer
    • Pick E, Kluger Y, Giltnane JM et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007; 67: 2932-7.
    • (2007) Cancer Res , vol.67 , pp. 2932-2937
    • Pick, E.1    Kluger, Y.2    Giltnane, J.M.3
  • 9
    • 35348890981 scopus 로고    scopus 로고
    • Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress
    • Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007; 1113: 202-16.
    • (2007) Ann N Y Acad Sci , vol.1113 , pp. 202-216
    • Workman, P.1    Burrows, F.2    Neckers, L.3    Rosen, N.4
  • 10
    • 58849160500 scopus 로고    scopus 로고
    • Heat shock protein 90 as a drug target: some like it hot
    • Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009; 15: 9-14.
    • (2009) Clin Cancer Res , vol.15 , pp. 9-14
    • Banerji, U.1
  • 11
    • 0043288724 scopus 로고    scopus 로고
    • Heat shock protein 90 as a molecular target for cancer therapeutics
    • Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213-7.
    • (2003) Cancer Cell , vol.3 , pp. 213-217
    • Isaacs, J.S.1    Xu, W.2    Neckers, L.3
  • 13
    • 37049183697 scopus 로고
    • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 14
    • 0026719644 scopus 로고
    • Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma
    • Jaehne J, Urmacher C, Thaler HT, Friedlander-Klar H, Cordon-Cardo C, Meyer HJ. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 474-9.
    • (1992) J Cancer Res Clin Oncol , vol.118 , pp. 474-479
    • Jaehne, J.1    Urmacher, C.2    Thaler, H.T.3    Friedlander-Klar, H.4    Cordon-Cardo, C.5    Meyer, H.J.6
  • 15
    • 0033561296 scopus 로고    scopus 로고
    • Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
    • Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18: 2149-64.
    • (1999) EMBO J , vol.18 , pp. 2149-2164
    • Siegel, P.M.1    Ryan, E.D.2    Cardiff, R.D.3    Muller, W.J.4
  • 16
    • 48649092620 scopus 로고    scopus 로고
    • A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
    • Lee-Hoeflich ST, Crocker L, Yao E et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-87.
    • (2008) Cancer Res , vol.68 , pp. 5878-5887
    • Lee-Hoeflich, S.T.1    Crocker, L.2    Yao, E.3
  • 17
    • 0042307325 scopus 로고    scopus 로고
    • The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    • Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003; 100: 8933-8.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 8933-8938
    • Holbro, T.1    Beerli, R.R.2    Maurer, F.3    Koziczak, M.4    Barbas III, C.F.5    Hynes, N.E.6
  • 18
    • 79955658799 scopus 로고    scopus 로고
    • Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
    • Campone M, Juin P, Andre F, Bachelot T. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit Rev Oncol Hematol 2011; 78: 195-205.
    • (2011) Crit Rev Oncol Hematol , vol.78 , pp. 195-205
    • Campone, M.1    Juin, P.2    Andre, F.3    Bachelot, T.4
  • 19
    • 67649472398 scopus 로고    scopus 로고
    • Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
    • Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
    • (2009) Nat Rev Cancer , vol.9 , pp. 463-475
    • Baselga, J.1    Swain, S.M.2
  • 20
    • 0036606332 scopus 로고    scopus 로고
    • Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway
    • Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 2002; 62: 3132-7.
    • (2002) Cancer Res , vol.62 , pp. 3132-3137
    • Munster, P.N.1    Marchion, D.C.2    Basso, A.D.3    Rosen, N.4
  • 21
    • 15544372341 scopus 로고    scopus 로고
    • Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex
    • Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat Struct Mol Biol 2005; 12: 120-6.
    • (2005) Nat Struct Mol Biol , vol.12 , pp. 120-126
    • Xu, W.1    Yuan, X.2    Xiang, Z.3    Mimnaugh, E.4    Marcu, M.5    Neckers, L.6
  • 22
    • 0029812759 scopus 로고    scopus 로고
    • Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin
    • Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996; 271: 22796-801.
    • (1996) J Biol Chem , vol.271 , pp. 22796-22801
    • Mimnaugh, E.G.1    Chavany, C.2    Neckers, L.3
  • 23
    • 54349098717 scopus 로고    scopus 로고
    • A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
    • Raja SM, Clubb RJ, Bhattacharyya M et al. A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 2008; 7: 1630-40.
    • (2008) Cancer Biol Ther , vol.7 , pp. 1630-1640
    • Raja, S.M.1    Clubb, R.J.2    Bhattacharyya, M.3
  • 24
    • 36849055007 scopus 로고    scopus 로고
    • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    • Modi S, Stopeck AT, Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25: 5410-7.
    • (2007) J Clin Oncol , vol.25 , pp. 5410-5417
    • Modi, S.1    Stopeck, A.T.2    Gordon, M.S.3
  • 25
    • 51449093764 scopus 로고    scopus 로고
    • Targeting Hsp90: small-molecule inhibitors and their clinical development
    • Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008; 8: 370-4.
    • (2008) Curr Opin Pharmacol , vol.8 , pp. 370-374
    • Taldone, T.1    Gozman, A.2    Maharaj, R.3    Chiosis, G.4
  • 26
    • 74249085361 scopus 로고    scopus 로고
    • Update on Hsp90 inhibitors in clinical trial
    • Kim YS, Alarcon SV, Lee S et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009; 9: 1479-92.
    • (2009) Curr Top Med Chem , vol.9 , pp. 1479-1492
    • Kim, Y.S.1    Alarcon, S.V.2    Lee, S.3
  • 27
    • 77952551024 scopus 로고    scopus 로고
    • Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
    • Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010; 14: 412-20.
    • (2010) Curr Opin Chem Biol , vol.14 , pp. 412-420
    • Porter, J.R.1    Fritz, C.C.2    Depew, K.M.3
  • 28
    • 80052573916 scopus 로고    scopus 로고
    • Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design
    • Miura T, Fukami TA, Hasegawa K et al. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design. Bioorg Med Chem Lett 2011; 21: 5778-83.
    • (2011) Bioorg Med Chem Lett , vol.21 , pp. 5778-5783
    • Miura, T.1    Fukami, T.A.2    Hasegawa, K.3
  • 29
    • 79955983369 scopus 로고    scopus 로고
    • The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations
    • Tanaka H, Yoshida M, Tanimura H et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011; 17: 3272-81.
    • (2011) Clin Cancer Res , vol.17 , pp. 3272-3281
    • Tanaka, H.1    Yoshida, M.2    Tanimura, H.3
  • 30
    • 77952994160 scopus 로고    scopus 로고
    • Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
    • Amin DN, Sergina N, Ahuja D et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2010; 2: 16ra7.
    • (2010) Sci Transl Med , vol.2
    • Amin, D.N.1    Sergina, N.2    Ahuja, D.3
  • 31
    • 33846552656 scopus 로고    scopus 로고
    • Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    • Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-41.
    • (2007) Nature , vol.445 , pp. 437-441
    • Sergina, N.V.1    Rausch, M.2    Wang, D.3
  • 32
    • 78651458656 scopus 로고    scopus 로고
    • AKT Inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
    • Chandarlapaty S, Sawai A, Scaltriti M et al. AKT Inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71.
    • (2011) Cancer Cell , vol.19 , pp. 58-71
    • Chandarlapaty, S.1    Sawai, A.2    Scaltriti, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.